

Brilliant Violet 421™ anti-mouse CD19 Antibody

Catalog# / Size	115537 / 125 µL 115549 / 50 µg 115538 / 500 µL
Clone	6D5
Regulatory Status	RUO
Other Names	B4
Isotype	Rat IgG2a, κ
Description	CD19 is a 95 kD glycoprotein also known as B4. It is a member of the Ig superfamily, expressed on all pro-B to mature B cells (during development) and follicular dendritic cells. Plasma cells do not express CD19. CD19, in association with CD21 and CD81, forms a molecular complex integral to B cell activation.

Product Details

Verified Reactivity	Mouse
Antibody Type	Monoclonal
Host Species	Rat
Immunogen	Mouse CD19-expressing K562 human erythroleukemia cells
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation	The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.
Concentration	µg sizes: 0.2 mg/mL µL sizes: lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
Storage & Handling	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application	FC - Quality tested IHC-F - Verified
Recommended Usage	<p>Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤ 0.25 µg per million cells in 100 µl volume. For immunofluorescent staining using µl sizes, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. For immunohistochemistry on Frozen tissue using the µg size, a concentration range of 1.0 - 5.0 µg/ml is suggested. It is recommended that the reagent be titrated for optimal performance for each application.</p> <p>Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.</p> <p>Learn more about Brilliant Violet™.</p> <p>This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.</p>
Excitation Laser	Violet Laser (405 nm)
Application Notes	Additional reported applications (for the relevant formats) include: immunofluorescence ⁷ .

Application References

(PubMed link indicates
BioLegend citation)

1. Shoham T, *et al.* 2003. *J. Immunol.* 171:4062. (FC)
2. Goodyear CS, *et al.* 2004. *J. Immunol.* 172:2870. (FC)
3. Kamimura D, *et al.* 2006. *J. Immunol.* 177:306. (FC)
4. Andoniou CE, *et al.* 2005. *Nat. Immunol.* 6:1011. (FC)
5. Lawson BR, *et al.* 2007. *J. Immunol.* 178:5366. (FC)
6. Phan TG, *et al.* 2007. *Nat. Immunol.* 8:992. (FC)
7. Hayashida K, *et al.* 2008. *J. Biol. Chem.* 283:19895. (IF) [PubMed](#)
8. Charles N, *et al.* 2010. *Nat. Med.* 16:701. (FC) [PubMed](#)
9. Bankoti J, *et al.* 2010. *Toxicol. Sci.* 115:422. (FC) [PubMed](#)
10. Stadnisky MD, *et al.* 2011. *Blood.* 117:5133. (FC) [PubMed](#)
11. Perlot T, *et al.* 2012. *J. Immunol.* 188:1201. (FC) [PubMed](#)
12. Olive V, *et al.* 2013. *Elife.* 2:822. [PubMed](#)
13. Miyai T, *et al.* 2014. *PNAS.* 111:11780. [PubMed](#)

Product Citations

1. Webster P, *et al.* 2018. *Nat Commun.* 9:2649. [PubMed](#)
2. Michela Miani *et al.* 2018. *Cell metabolism.* 28(4):557-572. [PubMed](#)
3. Djokić V, *et al.* 2019. *Front Immunol.* 9:2891. [PubMed](#)
4. Sadtler K, *et al.* 2017. *Tissue Eng Part A.* 23:1044. [PubMed](#)
5. Minutti CM, *et al.* 2019. *Immunity.* 50:645. [PubMed](#)
6. Lee CG, *et al.* 2019. *JCI Insight.* 4:5. [PubMed](#)
7. Schoeler K, *et al.* 2019. *FEBS J.* 10.1111/febs.14934. [PubMed](#)
8. Britton GJ *et al.* 2019. *Immunity.* 50(1):212-224. [PubMed](#)
9. Kim CJ, *et al.* 2018. *Immunity.* 49:1034. [PubMed](#)
10. Alexander Mildner *et al.* 2017. *Immunity.* 46(5):849-862. [PubMed](#)
11. Jiang W, *et al.* 2017. *Sci Rep.* 7:6501. [PubMed](#)
12. Maluski M, *et al.* 2019. *J Clin Invest.* 129:5108. [PubMed](#)
13. Fleskens V, *et al.* 2019. *Cell Rep.* 26:3600. [PubMed](#)
14. Jackson-Jones LH, *et al.* 2020. *Immunity.* 52:700. [PubMed](#)
15. Zheng Z, *et al.* 2020. *Cell Reports.* 31(13):107819. [PubMed](#)
16. Sangesland M, *et al.* 2020. *Immunity.* 51(4):735-749. [PubMed](#)
17. Brown CC, *et al.* 2020. *Cell.* 179(4):846-863.e24. [PubMed](#)
18. Rosalia R, *et al.* 2013. *Immunobiology.* 218:851. [PubMed](#)
19. Weber G, *et al.* 2014. *J Exp Med.* 211:1243. [PubMed](#)
20. Prooyen N, *et al.* 2016. *PLoS One.* 12: 1005749. [PubMed](#)
21. Kleiman E, *et al.* 2016. *Proc Natl Acad Sci U S A.* 113: E3911 - E3920. [PubMed](#)
22. Dibra D, *et al.* 2016. *Clin Cancer Res.* 22: 3876 - 3883. [PubMed](#)
23. Schaum N, *et al.* 2020. *Nature.* 583:596. [PubMed](#)
24. Kerkhofs D, *et al.* 2020. *Theranostics.* 7.022222222. [PubMed](#)
25. Xu G, *et al.* 2020. *Cell Rep.* 32:108170. [PubMed](#)
26. Evgin L, *et al.* 2020. *Nat Commun.* 2.671527778. [PubMed](#)
27. Wang Y, *et al.* 2020. *Immunity.* 53(6):1151-1167.e6. [PubMed](#)
28. Yilmaz B, *et al.* 2021. *Cell Host Microbe.* 29(4):650-663.e9. [PubMed](#)
29. Kawakami R, *et al.* 2021. *Immunity.* 54(5):947-961.e8. [PubMed](#)
30. Giampazolias E, *et al.* 2021. *Cell.* [PubMed](#)

RRID

AB_10895761 (BioLegend Cat. No. 115537)
AB_2563066 (BioLegend Cat. No. 115549)
AB_11203527 (BioLegend Cat. No. 115538)

Antigen Details

Structure	Ig superfamily, associates with CD21 and CD81, 95 kD
Distribution	Pro-B cells to mature B cells (during development), follicular dendritic cells
Function	Modulates B cell activation and differentiation
Ligand/Receptor	CD21, CD81, Leu-13
Cell Type	B cells, Dendritic cells
Biology Area	Costimulatory Molecules, Immunology
Molecular Family	CD Molecules
Antigen References	<ol style="list-style-type: none">1. Fearon DT. 1993. <i>Curr. Opin. Immunol.</i> 5:341.2. Krop I, <i>et al.</i> 1996. <i>Eur. J. Immunol.</i> 26:238.3. Krop I, <i>et al.</i> 1996. <i>J. Immunol.</i> 157:48.4. Tedder TF, <i>et al.</i> 1994. <i>Immunol. Today</i> 15:437.
Gene ID	12478


Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)


Other Formats

APC anti-mouse CD19, Biotin anti-mouse CD19, FITC anti-mouse CD19, PE anti-mouse CD19, PE/Cyanine5 anti-mouse CD19, Purified anti-mouse CD19, PE/Cyanine7 anti-mouse CD19, Alexa Fluor® 488 anti-mouse CD19, Alexa Fluor® 647 anti-mouse CD19, Pacific Blue™ anti-mouse CD19, Alexa Fluor® 700 anti-mouse CD19, APC/Cyanine7 anti-mouse CD19, PerCP anti-mouse CD19, PerCP/Cyanine5.5 anti-mouse CD19, Alexa Fluor® 594 anti-mouse CD19, Brilliant Violet 421™ anti-mouse CD19, Brilliant Violet 570™ anti-mouse CD19, Brilliant Violet 605™ anti-mouse CD19, Brilliant Violet 650™ anti-mouse CD19, Brilliant Violet 785™ anti-mouse CD19, Brilliant Violet 510™ anti-mouse CD19, Purified anti-mouse CD19 (Maxpar® Ready), PE/Dazzle™ 594 anti-mouse CD19, Brilliant Violet 711™ anti-mouse CD19, APC/Fire™ 750 anti-mouse CD19, TotalSeq™-A0093 anti-mouse CD19, Brilliant Violet 750™ anti-mouse CD19, TotalSeq™-B0093 anti-mouse CD19, Spark Blue™ 550 anti-mouse CD19, Spark NIR™ 685 anti-mouse CD19, TotalSeq™-C0093 anti-mouse CD19, Ultra-LEAF™ Purified anti-mouse CD19, PE/Fire™ 640 anti-mouse CD19 Antibody, Spark YG™ 581 anti-mouse CD19, APC/Fire™ 810 anti-mouse CD19, Spark YG™ 570 anti-mouse CD19, Spark Blue™ 574 anti-mouse CD19 Antibody

Product Data



C57BL/6 mouse splenocytes were stained with CD19 (clone 6D5) Brilliant Violet 421™ (filled histogram) or rat IgG2a, κ Brilliant Violet 421™ isotype control (open histogram).



C57BL/6 mouse frozen spleen section was fixed with 4% paraformaldehyde (PFA) for 10 minutes at room temperature and blocked with 5% FBS plus 5% rat serum for 1 hour at room temperature. Then the section was stained with 2.5 µg/ml of CD19 (clone 6D5) Brilliant Violet 421™, 2.5 µg/ml of CD3 (clone 17A2) Alexa Fluor® 594 (red) and 2.5 µg/ml of CD11b (clone M1/70) Alexa Fluor® 488 (green) overnight at 4°C. The image was captured by 10X objective.

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587